Extreme adiposity in a young population that has not yet converted it into mortality.

Why Belize

Belize has the third-highest adult obesity prevalence in the network at 41.7%, and 71.8% of adults are overweight or obese — yet its premature NCD mortality is among the lowest. That combination describes a large, young, high-BMI, cardiometabolically at-risk population that has not yet progressed to end-organ disease. For prevention, early-intervention and weight-management protocols, that is precisely the population you want and rarely find.

The disease burden

The obesity figures are stark: 51.8% of adult women and 31.6% of adult men meet the obesity threshold, and 79.3% of women are overweight or obese. Set against age-adjusted NCD mortality of 452 per 100,000 (PAHO Health in the Americas, 2019) — the lowest of the larger mainland and southern territories — this is a population early in the cardiometabolic disease trajectory rather than at the end of it.

Sites and infrastructure

• Karl Heusner Memorial Hospital, Belize City — the national referral hospital, 134 beds, with the Bliss School of Nursing on site
• Belize Health Information System — a country-wide integrated patient-centred electronic health record, unusually strong for a country of this size and a genuine asset for feasibility and pre-screening
• Medical schools are offshore and international-student institutions (Central America Health Sciences University, Grace University, Medical University of the Americas) rather than national research faculties

Research heritage

The Belize Vector and Ecology Center, Orange Walk — a permanent field research centre operated by the University of Notre Dame, focused on vector-borne disease entomology and intervention trials. It is infectious-disease rather than NCD work, but it demonstrates that a long-term US-academic field research operation can be run successfully in Belize.

Regulatory & ethics

• Drug Inspectorate Unit, Ministry of Health & Wellness
• Belize achieved full membership of the WHO Programme for International Drug Monitoring in June 2026, announced July 2026
• University of Belize Institutional Review Board — institutional remit; no national biomedical research ethics committee identified

The honest position: The medicines regulator is a small inspectorate unit that only reached full WHO PIDM membership in mid-2026, and no national research ethics committee could be identified — review would run through the University of Belize IRB. There is no track record of authorising interventional trials. Realistic positioning: Belize is a strong population with weak regulatory infrastructure, and the operating model has to account for that.

Data quality: Moderate — mortality and demographic data are good and the national EHR is a real asset, but NCD risk-factor intervals are very wide (diabetes 8.2–27.7), indicating almost no recent national biomarker survey.

How this site fits the network

Core network site — strong population proposition with a functioning ethics route; research infrastructure developing.

Our Belize operation is contracted, trained and monitored under the same quality system as our UK and US sites. One master service agreement covers all three regions, one budget negotiation, one set of payment terms. Sites in this network can absorb enrolment from under-recruiting UK or US centres without a new vendor qualification cycle.